Tirzepatide(tir zep' a tide)

In trial-grade comparisons, tirzepatide produces greater body-weight reduction than semaglutide on average: ~20% at 72 weeks (SURMOUNT-1) vs ~15% at 68 weeks (STEP-1). Individual response varies — some patients respond better to one molecule than the other. The mechanism difference (tirzepatide hits both GLP-1 and GIP receptors; semaglutide only GLP-1) is the leading hypothesis for the efficacy difference, though long-term head-to-head trials remain limited.

From the Zepbound editorial review.

Same active ingredient (tirzepatide), same dose strengths, same titration schedule, different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and (since late 2024) moderate-to-severe obstructive sleep apnea in adults with obesity. The pen device and dose ladder are identical. Coverage and pricing differ by indication.

From the Zepbound editorial review.

Appetite reduction often begins within 1–2 weeks of starting the 2.5 mg dose. Measurable weight loss typically appears by week 4. Trial participants achieved ~6% body weight loss by week 12, ~15% by week 28, and ~20% by week 72 at the 15 mg maintenance dose. Steady weekly weight loss of 1–2 lbs is typical during active titration.

From the Zepbound editorial review.

Yes, with clinician oversight. Most clinicians start tirzepatide at 2.5 mg weekly regardless of prior semaglutide dose — the molecules differ, and starting low reduces side-effect risk during the transition. Allow 1 week from the last Wegovy dose before starting Zepbound. Insurance considerations differ between drugs; check coverage before switching mid-prescription.

From the Zepbound editorial review.

Trial data show similar overall side-effect rates between tirzepatide and semaglutide. Anecdotally, some patients report stronger nausea on tirzepatide at equipotent weight-loss doses; others tolerate it better. The dual-receptor mechanism may produce a different GI symptom profile. Slower titration (8 weeks per step instead of 4) often improves tolerance dramatically.

From the Zepbound editorial review.

Coverage is improving rapidly through 2025–2026 as more plans add weight-management coverage. Most commercial plans now cover Zepbound with prior authorization — typically requiring BMI documentation, comorbidity, and prior lifestyle attempts. Medicare Part D does not cover weight-loss drugs by statute. State Medicaid coverage varies. Many employer-sponsored plans exclude weight-loss medications; check before initiation.

From the Zepbound editorial review.

Yes — Zepbound received FDA approval in late 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials. Mechanism: weight loss reduces upper-airway soft-tissue obstruction, often improving or resolving OSA. Patients with documented OSA may have a more straightforward insurance pathway under the OSA indication than under obesity alone.

From the Zepbound editorial review.